Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Ansam Mazin Butrous; Newsherwan  Sadiq Muhammad

doi:10.15218/zjms.2023.028

Authors

Ansam Mazin Butrous Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.
Newsherwan Sadiq Muhammad Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2023.028

Keywords:

Chronic lymphocytic leukemia, Lymphoproliferative neoplasms, Immunophenotyping, Flow cytometry

Abstract

Background and objective: Chronic lymphocytic leukemia (CLL) is a clonal, mature B-cell neoplasm, its clinical features, cell morphology, and immunophenotyping are used to establish the diagnosis. Immunophenotyping by flow cytometry is the most accurate procedure for diagnosing CLL, there is no single marker exclusively expressed in CLL, however, a complex of immunophenotypic markers that incorporates several B-cell markers and assists in differentiating CLL from other mature B-cell neoplasms, the expression of these immunophenotypic markers is considered in the specific CLL scoring system (Moreue scoring system).this study aimed to assess the clinico – hematological features and immunophenotypic characteristics of CLL patients and to assess the role of immunophenotyping in the differential diagnosis of CLL.

Methods: an observational prospective and retrospective study was carried out at Nanakaly hospital for blood diseases and oncology in Erbil city, Iraq. That was conducted on 100 patients newly diagnosed with mature B cell neoplasm which included 68 cases of CLL and 32 cases with other mature B cell neoplasm (MBN), usinga convenience sampling method. The study period was from the1^st of September 2021 to the end of April 2022. An interview questionnaire was used to collect the study data from the patients.

Results: The mean of age ± standard deviation of the CLL patients (58.85 ± 10.69) years and (66.2%) was male, The most frequent clinical presentations for CLL cases were fatigue (50%), lymphadenopathy (41.2%), and splenomegaly (41.2%), (50%) of CLL patients had anemia, thrombocytopenia was seen in (32.4%) and leukocytosis was seen (98.5%), all patients had lymphocytosis and (97%) had an absolute B lymphocyte count of more than 5 x10⁹/L. all the studied CLL patients expressed both CD45 and CD19 markers, the expression of the immunophenotypic markers was as following: CD5 (98.5%), CD23 (97.1%) and CD200 (97.1%), Half of the patients (50%) showed expression of monoclonal lambda light chain, sIgM (4.4%), CD20 (88.2%) and CD43 (54.4%) and CD38 (26.5%). The expression of the following marker had a significant role in the differentiation between CLL and other MBN: CD5, CD23, CD79b, FMC7, sIgM, CD200, and CD43.

Conclusion: Ourresults have shown that the clinical presentations and hematological profile of Iraqi CLL patients were not significantly different from that of previous local and global studies, the distinct immunophenotyping, as well as it has been found that immunophenotyping is a promising method for supporting the clinical and morphological characterization of CLL.

Metrics

Metrics Loading ...

References

Hsi ED. 2016 WHO Classification update—What’s new in lymphoid neoplasms. International Journal of Laboratory Hematology 2017; 39(S1):14–22. https://doi.org/10.1111/ijlh.12650

Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, et al. “Double-hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain. American Journal of Hematology 2018; 93(3):37582. https://doi.org/10.1002/ajh.24990

Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, et al. Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia. Cancer Cell 2011; 20(2):246–59. https://doi.org/10.1016/j.ccr.2011.06.029

Chang JC, Harrington AM, Olteanu H, VanTuinen P, Kroft SH. Proliferation centers in bone marrows involved by chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic analysis. Annals of Diagnostic Pathology 2016; 25:15–9. https://doi.org/10.1016/j.anndiagpath.2016.07.011

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569

Rahimi H, Sadeghian MH, Keramati MR, Jafarian AH, Shakeri S, Shams SF, et al. Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran. Int J Hematol Oncol Stem Cell Res 2017; 11(3):217–24. PMID: 28989588

Payandeh M, Sadeghi E, Sadeghi M. Survival and Clinical Aspects for Patients with Chronic Lymphocytic Leukemia in Kermanshah, Iran. Asian Pacific Journal of Cancer Prevention 2015; 16(17):7987–90. https://doi: 10.7314/apjcp.2015.16.17.7987.

Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology 2019; 94(11):1266–87. https://doi.org/10.1002/ajh.25595

Vosoughi T, Bagheri M, Hosseinzadeh M, Ehsanpour A, Davari N, Saki N. CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. J Cell Physiol 2019; 234(11):19420–39. https://doi.org/10.1002/jcp.28724

Bagheri M, Vosoughi T, Hosseinzadeh M, Saki N. Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes 2020; 13(1):412. https://doi.org/10.1186/s13104-020-05243-7

Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology 2017; 92(9):946–65. https://doi.org/10.1002/ajh.24826

Dragović-Ivančević T, Kraguljac-Kurtović N, Knežević V, Bogdanović A, Mihaljević B, Božić B, et al. The role of immunophenotyping in differential diagnosis of chronic lymphocytic leukemia. Srpski arhiv za celokupnolekarstvo 2014; 142(3–4):197–203. https://doi.org/10.2298/SARH1404197D

Abbas HR, Al-Mashta MAR. Flowcytometry aiding morphological diagnosis of mature B-cell neoplasm in patients with lymphocytosis. Medical Journal of Babylon 2021; 18(4):364. https://DOI: 10.4103/MJBL.MJBL_51_21

Ozdemir ZN, Falay M, Parmaksiz A, Genc E, Beyler O, Gunes AK, et al. A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry. Hematology, Transfusion and Cell Therapy 2021. https://www.sciencedirect.com/science/article/pii/S2531137921013171. https://doi.org/10.1016/j.htct.2021.08.012

Hasan KM. Clinical Aspects, Immunophenotypic Analysis and Survival Rate of Chronic Lymphocytic Leukaemia Patients in Erbil City, Iraq. Sultan Qaboos Univ Med J 2018; 18(4):e461–7. https://doi: 10.18295/squmj.2018.18.04.006

Vasylyev A, Loginov A, Molostvova V, Rebrov B, Pereira MHS, Melo CWA, et al. Prevalence and cumulative 5-year incidence of chronic lymphocytic leukemia in the adult population in the Russian Federation and Ukraine: Data from the LEUKOSPECT study. Hematology 2017; 22(1):16–24. https://doi.org/10.1080/10245332.2016.1201630

Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology 2015; 90(5):446–60. https://doi.org/10.1002/ajh.23979

Padaro E, Layibo Y, Kueviakoe IDM, Agbétiafa K, Magnang H, Koudokpo NDA, et al. Caractéristiques de la leucémie lymphoïde chronique au Togo. Pan Afr Med J 2019; 34:84. https://DOI : 10.11604/pamj.2019.34.84.18752

Nabhan C, Aschebrook-Kilfoy B, Chiu BCH, Smith SM, Shanafelt TD, Evens AM, et al. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. Leukemia & Lymphoma 2014; 55(12):2778–84. https://doi.org/10.3109/10428194.2014.898758

Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. The Lancet 2018; 391(10129):1524–37. https://doi.org/10.1016/S0140-6736(18)30422-7

Kamel AM, El-Sharkawy NM, Osman RA, Abd El-Fattah EK, El-Noshokaty E, Abd El-Hamid T, et al. Adhesion molecules expression in CLL: Potential impact on clinical and hematological parameters. Journal of the Egyptian National Cancer Institute 2016; 28(1):31–7. https://doi.org/10.1016/j.jnci.2016.01.003

Sall A, Touré AO, Sall FB, Ndour M, Fall S, Sène A, et al. Characteristics of chronic lymphocytic leukemia in Senegal. BMC Hematology 2016; 16(1):10. https://doi.org/10.1186/s12878-016-0051-y

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B: Clinical Cytometry 2018; 94(1):121–8. https://doi.org/10.1002/cyto.b.21595

Rodrigues CA, Gonçalves MV, Ikoma MRV, Lorand-Metze I, Pereira AD, Farias DLC de, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter 2016; 38:34657. https://doi.org/10.1016/j.bjhh.2016.07.004

Falay M, Özet G. Immunophenotyping of Chronic Lymphocytic Leukemia. Clinical laboratory 2017; 63:1621–6. https://DOI: 10.7754/Clin.Lab.2017.170406

Hendy O, Shafie ME, Allam M, Motalib T, Khalaf F, Gohar S. The diagnostic and prognostic value of CD38 and CD49d expressions in chronic lymphocytic leukemia. The Egyptian Journal of Haematology 2016; 41(2):70–70. https://DOI: 10.4103/1110-1067.186409

Starostka D, Kriegova E, Kudelka M, Mikula P, Zehnalova S, Radvansky M, et al. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms. Cytometry Part B: Clinical Cytometry 2018; 94(4):576–87. https://doi.org/10.1002/cyto.b.21607

Falay M, Afacan Öztürk B, Güneş K, Kalpakçı Y, Dağdaş S, Ceran F, et al. The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. Turk J Haematol 2018; 35(2):94–8. https://doi: 10.4274/tjh.2017.0085

Starostka D, Kriegova E, Kudelka M, Mikula P, Zehnalova S, Radvansky M, et al. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms. Cytometry Part B: Clinical Cytometry 2018; 94(4):576–87. https://doi.org/10.1002/cyto.b.21607

Sawhney J, Singh A, Rahiya B. Role and relevance of the euroflow antibody panel in immunophenotyping of chronic lymphoproliferative disorders. IJAR 2020; 1–4. https:// DOI : 10.36106/ijar

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131(25):2745–60. https://doi.org/10.1182/blood-2017-09-806398

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526(7574):519–24. https://doi.org/10.1038/nature14666

Marrero YT, Suárez VM, Pérez YD, Domínguez GD, Hernández IC, Ramos EH, et al. Immunophenotypic Characterization by Flow Cytometry of Chronic Lymphoid Leukemia. Journal of Cancer Immunology 2021; 3(4):196–205. https://doi.org/10.33696/haematology.1.009

Köhnke T, Wittmann VK, Bücklein VL, Lichtenegger F, Pasalic Z, Hiddemann W, et al. Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200. British Journal of Haematology 2017; 179(3):480–7. https://doi.org/10.1111/bjh.14901

Li Y, Tong X, Huang L, Li L, Wang C, He C, et al. A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Medicine 2021; 10(13):4387–96. https://doi.org/10.1002/cam4.3983